Future FinTech Signs Framework Agreement to Acquire TransGen SC Tech Limited Expanding into the Biomedical R&D Sector
Rhea-AI Summary
Future FinTech (NASDAQ:FTFT) said its subsidiary Future FinTech (Hong Kong) Limited signed a Framework Agreement on Jan 7, 2026 to acquire 100% of TransGen SC Tech Limited, a biomedical R&D company focused on diabetes, Alzheimer’s and microalgal extracellular vesicle drug-delivery research.
The acquisition is expected to complete within 90 calendar days subject to due diligence and a financial audit; a definitive agreement will follow a satisfactory outcome. TransGen holds 26 invention and utility patents and certifications including Level 2 Biosafety Laboratory and Human Umbilical Cord Mesenchymal Stem Cells qualification.
Positive
- Framework agreement to acquire 100% of TransGen signed on Jan 7, 2026
- TransGen holds 26 invention and utility patents
- TransGen has Level 2 Biosafety Laboratory certification and stem cell qualification
- Deal aims to diversify FTFT into biomedical R&D and leverage fintech capabilities for funding
Negative
- Completion is conditional: subject to due diligence and financial audit
- No financial terms or purchase price were disclosed
- Targeted closing timeline of 90 calendar days is an expectation, not guaranteed
News Market Reaction
On the day this news was published, FTFT declined 9.25%, reflecting a notable negative market reaction. Argus tracked a peak move of +4.8% during that session. Argus tracked a trough of -18.6% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $17M at that time. Trading volume was elevated at 2.2x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers showed mixed moves: JTAI appeared in momentum scanners up 5.34%, while MASK was down 8.54%. With FTFT’s own direction not specified and peers split between gains and losses, the setup points to stock-specific drivers rather than a unified sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Crypto partnership LOI | Positive | +11.1% | LOI with S1Quant to build compliant quantitative crypto asset management products. |
| Oct 07 | Web3/RWA cooperation | Positive | +8.9% | Strategic cooperation with HHEX to accelerate Web3 and RWA tokenization platforms. |
| Sep 02 | Rail JV announcement | Positive | -5.4% | JV to commercialize patented ultra‑high‑speed rail ‘Vacuum Parcel’ transport technology. |
| Aug 27 | Shareholder meeting notice | Neutral | +3.2% | Announcement of special shareholder meeting and voting logistics for investors. |
| Aug 13 | AI trading platform | Positive | +3.4% | Launch of AI-driven analytics and trading platform via Hong Kong securities subsidiary. |
Strategic and tech-focused announcements have often seen positive immediate reactions, though one large infrastructure deal saw a negative divergence.
Over the past six months, FTFT has reported several strategic initiatives across crypto, Web3, AI and infrastructure. A crypto asset-management LOI on Jan 5, 2026 and a Web3/RWA cooperation in Oct 2025 both coincided with double‑digit and high‑single‑digit gains. An advanced rail transport joint venture in Sep 2025 drew a negative reaction despite its scale. AI trading tools and corporate governance events in Aug 2025 saw modest gains. Today’s biomedical acquisition framework continues this diversification trajectory into new verticals.
Market Pulse Summary
The stock moved -9.3% in the session following this news. A negative reaction despite expansion news fits a pattern where the market at times discounted ambitious projects, as seen with the rail initiative. Regulatory filings highlighted continued losses and going‑concern language, which may keep pressure on the equity when new ventures surface. Investors evaluating a selloff around this deal might weigh balance-sheet strain, integration risk, and whether the shift toward biomedical R&D adds near‑term uncertainty.
Key Terms
microalgal extracellular vesicles medical
nanocarriers medical
mesenchymal stem cells medical
biosafety laboratory medical
extracellular vesicles medical
AI-generated analysis. Not financial advice.
Pursuant to the Agreement, the acquisition is expected to be completed within 90 calendar days subject to due diligence and a financial audit of TransGen. A formal acquisition agreement will be executed upon a satisfactory outcome, after which both parties will sign a definitive agreement.
TransGen has established a solid foundation in biofactor R&D, which entails processes that leverage naturally occurring compounds that support normal physiological functioning and that have health-promoting effects on disease prevention and overall wellness. TransGen's primary focus is on the high-value therapeutic areas of developing treatments for diabetes and Alzheimer's disease.
TransGen also conducts advanced research on the enrichment and functional properties of microalgal extracellular vesicles – naturally secreted nanoparticles from microalgae. These serve as next-generation nanocarriers for targeted drug delivery and diagnostics by harnessing their natural ability to transfer beneficial biological molecules. TransGen holds 26 invention patents and utility model patents. This includes numerous certifications and designations, including:
Level 2 Biosafety Laboratory Certification, which refers to standards and protocols for laboratories involved in moderate risk infectious agents, which is regulated by
Human Umbilical Cord Mesenchymal Stem Cells Qualification Certificate, that ensures the quality and safety of pharmaceuticals and biological products, issued by
TransGen has also played an instrumental role in the formulation of the group standard "Specification for Isolation and Preparation of Adipose-Derived Mesenchymal Stem Cells" and the local standard "Standards and Management Specifications for Human Mesenchymal Stem Cell Banks", underscoring its strong technological capabilities and recognized leadership within the industry.
Gai Wei, Director of TransGen, said, "TransGen focuses on technology R&D and industrialization in the biomedical field, possesses core technologies and compliance qualifications in areas such as biofactor therapy and microalgal extracellular vesicle research, and is committed to improving human health and well-being through biological innovation technologies. The signing of this agreement with Future Fintech marks a pivotal step for TransGen to partner with a globally resourced company to advance its international expansion strategy."
Hu Li, CEO of FTFT, stated, "The signing of this agreement represents our strategic plan to diversify into the biomedical sector since TransGen is poised for high growth and is well positioned in a large market driven by an aging population and rising healthcare spending. Further, our fintech capabilities in risk modeling, securitization and capital markets can be used to structure innovative funding vehicles for medical-device initiatives, turning biomedical R&D into investable products. We also see synergies for FTFT since secure identity, payments, and data sharing are critical in both finance and healthcare. This acquisition will help to promote the industrialization of TransGen technologies while delivering diversified long-term value for our shareholders."
About Future Fintech Group Inc.
Future FinTech Group Inc. (NASDAQ: FTFT) is a comprehensive financial and digital technology service provider. The Company, through its subsidiaries, conducts brokerage and investment banking services in
Safe Harbor Statement
Certain statements made in this press release are "forward-looking statements" within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include statements regarding our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties, and other factors that may be beyond our control, which may cause the actual results, performance, capital, ownership, or achievements of the Company to be materially different from those implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements by our use of words such as "may," "will," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "estimate," "continue," "plan," "point to," "project," "could," "intend," "target" and other similar words and expressions relating to the future.
All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, the risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2024 and our other reports and filings with the SEC. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC's Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise, or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements are otherwise made.
View original content to download multimedia:https://www.prnewswire.com/news-releases/future-fintech-signs-framework-agreement-to-acquire-transgen-sc-tech-limited-expanding-into-the-biomedical-rd-sector-302655687.html
SOURCE Future FinTech Group Inc.
FAQ
What did FTFT announce about acquiring TransGen on Jan 7, 2026?
What technologies and therapeutic areas does TransGen focus on for FTFT shareholders?
How many patents and certifications does TransGen hold as described in the announcement?
When will the FTFT-TransGen acquisition be finalized and what conditions apply?
Did FTFT disclose the purchase price or financing details for TransGen?
